Cancer mortality and competing causes of death in older adults with cancer: A prospective, multicentre cohort study (ELCAPA-19).
cancer
cause of death
geriatric assessment
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
15
09
2023
received:
19
06
2023
accepted:
13
10
2023
pubmed:
8
11
2023
medline:
8
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
In older patients with cancer, comorbidities compete with cancer for cause of death. The objectives were to evaluate cancer mortality and factors associated, according to metastatic status. Between 2007 and 2014, patients with cancer aged ≥70 referred for pre-therapeutic geriatric assessment (GA) were included through the ELCAPA prospective cohort study. The underlying cause of death was defined according to the International Classification of Diseases, 10th Revision. The World Health Organisation definition was used to categorise the cause of death as cancer versus another disease (e.g. cardiovascular disease, infectious disease, etc.) Competing risk models were used. Mean (SD) age of the 1445 included patients was 80.2 (5.8) and 48% were women. Most common tumour sites were colorectal (19%), breast (17%) and urinary (15%); 773 patients (49%) had metastases. After a 34-month median follow-up, 706 cancer deaths were observed among 843 deaths. The 6-month and 3-year cancer mortality rates (95% CI) were 12% (9-15) and 34% (29-38) for non-metastatic patients and 43% (39-47) and 79% (75-82) for metastatic patients, respectively. Dependency in activities of daily living and comorbidities were associated with 6-month and 3-year cancer mortality in non-metastatic (adjusted subhazard ratio [aSHR] = 1.68 [0.99-2.85] and 1.69 [1.16-2.45]; and 1.98 [1.08-3.63] and 3.38 [1.47-7.76], respectively) and metastatic patients (aSHR = 2.81 [2.01-3.93] and 2.95 [2.14-4.07]; and 1.63 [1.18-2.25] and 2.06 [1.39-3.05], respectively). Impaired Timed-Get-Up-and-Go test was associated with 6-month and 3-year cancer mortality in metastatic patients (aSHR = 1.5 [1.06-2.12] and 1.38 [1.06-1.81], respectively). Obesity was negatively associated with 3-year cancer death in non-metastatic (aSHR = 0.53 [0.29-0.97]) and metastatic patients (aSHR = 0.71 [0.51-1.00]). The majority of older adults with cancer referred for pre-therapeutic GA die from cancer. Geriatric parameters are independently associated with cancer mortality and should be considered for prognosis assessment, decision-making and care.
Sections du résumé
BACKGROUND
BACKGROUND
In older patients with cancer, comorbidities compete with cancer for cause of death. The objectives were to evaluate cancer mortality and factors associated, according to metastatic status.
METHODS
METHODS
Between 2007 and 2014, patients with cancer aged ≥70 referred for pre-therapeutic geriatric assessment (GA) were included through the ELCAPA prospective cohort study. The underlying cause of death was defined according to the International Classification of Diseases, 10th Revision. The World Health Organisation definition was used to categorise the cause of death as cancer versus another disease (e.g. cardiovascular disease, infectious disease, etc.) Competing risk models were used.
RESULTS
RESULTS
Mean (SD) age of the 1445 included patients was 80.2 (5.8) and 48% were women. Most common tumour sites were colorectal (19%), breast (17%) and urinary (15%); 773 patients (49%) had metastases. After a 34-month median follow-up, 706 cancer deaths were observed among 843 deaths. The 6-month and 3-year cancer mortality rates (95% CI) were 12% (9-15) and 34% (29-38) for non-metastatic patients and 43% (39-47) and 79% (75-82) for metastatic patients, respectively. Dependency in activities of daily living and comorbidities were associated with 6-month and 3-year cancer mortality in non-metastatic (adjusted subhazard ratio [aSHR] = 1.68 [0.99-2.85] and 1.69 [1.16-2.45]; and 1.98 [1.08-3.63] and 3.38 [1.47-7.76], respectively) and metastatic patients (aSHR = 2.81 [2.01-3.93] and 2.95 [2.14-4.07]; and 1.63 [1.18-2.25] and 2.06 [1.39-3.05], respectively). Impaired Timed-Get-Up-and-Go test was associated with 6-month and 3-year cancer mortality in metastatic patients (aSHR = 1.5 [1.06-2.12] and 1.38 [1.06-1.81], respectively). Obesity was negatively associated with 3-year cancer death in non-metastatic (aSHR = 0.53 [0.29-0.97]) and metastatic patients (aSHR = 0.71 [0.51-1.00]).
CONCLUSIONS
CONCLUSIONS
The majority of older adults with cancer referred for pre-therapeutic GA die from cancer. Geriatric parameters are independently associated with cancer mortality and should be considered for prognosis assessment, decision-making and care.
Identifiants
pubmed: 37937731
doi: 10.1002/cam4.6639
pmc: PMC10709739
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20940-20952Subventions
Organisme : Cancéropôle Ile de France
Organisme : Gerontopôle Ile-de-France
Organisme : Institut National Du Cancer
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Br J Cancer. 2013 Apr 16;108(7):1534-40
pubmed: 23481180
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Cancer Med. 2023 Nov;12(22):20940-20952
pubmed: 37937731
Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
pubmed: 16084735
J Clin Oncol. 2012 May 20;30(15):1829-34
pubmed: 22508806
J Gerontol A Biol Sci Med Sci. 2020 Sep 25;75(10):1935-1942
pubmed: 31956891
J Gerontol A Biol Sci Med Sci. 2016 Dec;71(12):1653-1660
pubmed: 27006079
J Geriatr Oncol. 2013 Jul;4(3):227-34
pubmed: 23795224
J Am Geriatr Soc. 2009 Jan;57(1):24-30
pubmed: 19054189
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):255-64
pubmed: 25417239
Obes Rev. 2015 Jul;16(7):607-19
pubmed: 25925734
J Clin Oncol. 2016 Jul 10;34(20):2366-71
pubmed: 27185838
J Cancer Res Clin Oncol. 2016 May;142(5):1069-77
pubmed: 26758276
J Natl Cancer Inst. 2012 Aug 8;104(15):1133-63
pubmed: 22851269
J Clin Oncol. 2013 Oct 10;31(29):3711-8
pubmed: 24019549
World Health Stat Q. 1988;41(1):32-6
pubmed: 3376487
Cancer. 2010 Sep 15;116(18):4410-9
pubmed: 20564155
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Curr Oncol Rep. 2016 Sep;18(9):56
pubmed: 27475805
Rev Med Interne. 2016 Jul;37(7):480-8
pubmed: 26997159
J Epidemiol. 2016;26(4):191-8
pubmed: 26639750
Stat Med. 2017 Nov 30;36(27):4391-4400
pubmed: 28913837
Ann Oncol. 2011 Aug;22(8):1922-6
pubmed: 21266517
J Clin Oncol. 2016 May 1;34(13):1476-83
pubmed: 26884557
Cancer Control. 2014 Jul;21(3):215-20
pubmed: 24955705
J Gerontol A Biol Sci Med Sci. 2015 Sep;70(9):1148-55
pubmed: 25834194
Hematol Oncol Clin North Am. 2000 Feb;14(1):17-23
pubmed: 10680069
Eur J Cancer. 2018 Feb;90:10-18
pubmed: 29268140
Cancer. 2004 Nov 15;101(10):2276-84
pubmed: 15470712
J Nutr Health Aging. 2017;21(2):202-206
pubmed: 28112777
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
J Clin Oncol. 2011 Sep 20;29(27):3636-42
pubmed: 21709194
Clin Nutr. 2019 Dec;38(6):2806-2812
pubmed: 30583963
Urol Oncol. 2018 Jun;36(6):309.e15-309.e23
pubmed: 29576269
Cancer Epidemiol. 2018 Aug;55:39-44
pubmed: 29763754
J Clin Epidemiol. 2013 Jun;66(6):648-53
pubmed: 23415868
J Clin Oncol. 2011 Apr 20;29(12):1570-7
pubmed: 21402602
J Clin Oncol. 2011 Sep 20;29(27):3620-7
pubmed: 21859998
Support Care Cancer. 2016 Nov;24(11):4807-13
pubmed: 27465048
Ann Oncol. 2018 Jan 1;29(1):133-138
pubmed: 29045659